Travere Therapeutics (TVTX) Cash & Equivalents Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -51.77% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 24.73% |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -28.55% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 13.33% |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -16.07% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 21.66% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -8.88% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 36.53% |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn | -21.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.40% |
| Dec 31, 2025 | 14.68% |
| Sep 30, 2025 | -9.84% |
| Jun 30, 2025 | -25.23% |
| Mar 31, 2025 | -37.75% |
| Dec 31, 2024 | -29.32% |
| Sep 30, 2024 | -37.67% |
| Jun 30, 2024 | -27.08% |
| Mar 31, 2024 | -33.67% |
| Dec 31, 2023 | -11.79% |
| Sep 30, 2023 | -10.39% |
| Jun 30, 2023 | -33.14% |
| Mar 31, 2023 | 34.03% |
| Dec 31, 2022 | -0.40% |
| Sep 30, 2022 | 32.41% |
| Jun 30, 2022 | 33.44% |
| Mar 31, 2022 | 54.30% |
| Dec 31, 2021 | 17.23% |
| Sep 30, 2021 | -0.98% |
| Jun 30, 2021 | -2.30% |
| Mar 31, 2021 | 34.36% |
| Dec 31, 2020 | -5.17% |
| Sep 30, 2020 | 26.52% |
| Jun 30, 2020 | 38.50% |
| Mar 31, 2020 | 16.98% |
| Dec 31, 2019 | 15.05% |
| Sep 30, 2019 | 39.73% |
| Jun 30, 2019 | 52.93% |
| Mar 31, 2019 | 44.26% |
| Dec 31, 2018 | 39.61% |
| Sep 30, 2018 | 3.26% |
| Jun 30, 2018 | -11.25% |
| Mar 31, 2018 | -20.18% |
| Dec 31, 2017 | 76.09% |
| Sep 30, 2017 | 56.43% |
| Jun 30, 2017 | 30.81% |
| Mar 31, 2017 | 124.60% |
| Dec 31, 2016 | 89.80% |
| Sep 30, 2016 | 21.23% |